收稿日期: 2022-01-04
网络出版日期: 2022-08-17
基金资助
国家自然科学基金(81273295);国家自然科学基金(81671598);国家自然科学基金(81801 601);上海市自然科学基金(20ZR1451400);上海市科委医学创新基金(20Y11911600);上海吴孟超医学科技基金会(JJHXM-2019011);同济大学附属同济医院临床研究培育重点项目(ITJZD 1909)
汤建平, 龚邦东 . 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022 , 21(03) : 291 -298 . DOI: 10.16150/j.1671-2870.2022.03.001
| [1] | Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren′s syndrome[J/OL]. Rheumato-logy(Oxford),2019-02-15. https://pubmed.ncbi.nlm.nih.gov/30770918/. |
| [2] | Jaskólska M, Chylińska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjögren′s syndrome: a preliminary report[J]. Rheumatol Int, 2020, 40(8):1267-1274. |
| [3] | Ramos-Casals M, Brito-Zerón P, Solans R, et al. Systemic involvement in primary Sjögren′s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)[J]. Rheumatology (Oxford), 2014, 53(2):321-331. |
| [4] | Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren′s syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1):3-18. |
| [5] | 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59(4):269-276. |
| [5] | Zhang W, Li XM, Xu D, et al. Recommendations of diagnosis and treatment of primary Sjögren′s syndrome in China[J]. Chin J Intern Med, 2020, 59(4):269-276. |
| [6] | Mariette X, Criswell LA. Primary Sjögren′s Syndrome[J]. N Engl J Med, 2018, 378(10):931-939. |
| [7] | Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren′s syndrome: the JOQUER randomized clinical trial[J]. JAMA, 2014, 312(3):249-258. |
| [8] | van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren′s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial[J]. Lancet Rheumatol, 2020, 2:e260-e269. |
| [9] | Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren′s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren′s Syndrome(TRIPSS)[J]. Arthritis Rheum, 2004, 50(4):1270-1276. |
| [10] | Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren′s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial[J]. Arthritis Rheum, 2004, 50(7):2240-2245. |
| [11] | Norheim KB, Harboe E, G? ransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjögren′s syndrome--a double blind, randomised clinical trial[J]. PLoS One, 2012, 7(1):e30123. |
| [12] | Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren′s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study[J]. Ann Rheum Dis, 2008, 67(11):1541-1544. |
| [13] | Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren′s syndrome: a randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheum, 2010, 62(4):960-968. |
| [14] | Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren′s syndrome with rituximab: a randomized trial[J]. Ann Intern Med, 2014, 160(4):233-242. |
| [15] | Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren′s syndrome[J]. Arthritis Rheumatol, 2017, 69(7):1440-1450. |
| [16] | Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren′s syndrome: results of the BELISS open-label phase Ⅱ study[J]. Ann Rheum Dis, 2015, 74(3):526-531. |
| [17] | Shao Q. Biologic therapy in Sjögren′s syndrome[J]. Clin Rheumatol, 2021, 40(6):2143-2154. |
| [18] | Theander E, Jonsson R, Sjöström B, et al. Prediction of Sjögren′s Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling[J]. Arthritis Rheumatol, 2015, 67(9):2427-2436. |
| [19] | Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis[J]. Autoimmun Rev, 2019, 18(1):93-106. |
| [20] | Baldini C, Gallo A, Perez P, et al. Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren′s syndrome[J]. Clin Exp Rheumatol, 2012, 30(5):785-790. |
| [21] | Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjögren′s syndrome[J]. Arthritis Rheumatol, 2015, 67(9):2437-2446. |
| [22] | Reale M, D′Angelo C, Costantini E, et al. MicroRNA in Sjögren′s Syndrome: their potential roles in pathogenesis and diagnosis[J]. J Immunol Res, 2018, 2018:7510174. |
| [23] | US National Library of Medicine. Safety and efficacy study of subcutaneous belimumab and intravenous ritu-ximab co-administration in Subjects with primary Sjögren′s syndrome[EB/OL]. 2020[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT02631538. |
| [24] | Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren′s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity[J]. Ann Rheum Dis, 2019, 78(5):641-647. |
| [25] | Fisher BA, Szanto A, Ng AF, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren′s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study[J]. Lancet Rheumatol, 2020, 2:e142-e152. |
| [26] | Rivière E, Pascaud J, Tchitchek N, et al. Salivary gland epithelial cells from patients with Sjögren′s syndrome induce B-lymphocyte survival and activation[J]. Ann Rheum Dis, 2020, 79(11):1468-1477. |
| [27] | Juarez M, Diaz N, Johnston GI, et al. A phase 2 rando-mized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren′s syndrome[J]. Rheumatology (Oxford), 2021, 60(3):1364-1375. |
| [28] | Pitzalis C, Jones GW, Bombardieri M, et al. Ectopic lymphoid-like structures in infection, cancer and autoimmunity[J]. Nat Rev Immunol, 2014, 14(7):447-462. |
| [29] | St Clair EW, Baer AN, Wei C, et al. Clinical efficacy and safety of baminercept, a lymphotoxin β receptor fusion protein, in primary Sjögren′s syndrome: results from a phase Ⅱ randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2018, 70(9):1470-1480. |
| [30] | Mariette X, Bombardieri M, Alevizos I, et al. A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sjögren′s syndrome[J]. Arthritis Rheumatol, 2019, 71(Suppl 10):2417. |
| [31] | van Nimwegen JF, Mossel E, van Zuiden GS, et al. Abatacept treatment for patients with early active primary Sjögren′s syndrome: a single-centre, randomised, double-blind, placebocontrolled, phase 3 trial (ASAP-Ⅲ study)[J]. Lancet Rheumatol, 2020, 2:e153-e163. |
| [32] | Baer AN, Gottenberg JE, St Clair EW, et al. Efficacy and safety of abatacept in active primary Sjögren′s syndrome: results of a phase Ⅲ, randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2021, 80(3):339-348. |
| [33] | US National Library of Medicine. Safety of tofacitinib, an oral janus kinase inhibitor, in primary Sjögren′s syndrome[EB/OL].2021[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT04496960. |
| [34] | US National Library of Medicine. Pilot Trial of Usteki-numab for Primary Sjögren′s Syndrome[EB/OL]. 2021[2022-01-04]. https://clinicaltrials.gov/ct2/show/NCT04093531. |
| [35] | Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren′s syndrome[J]. Blood, 2012, 120(15):3142-3151. |
| [36] | Gong B, Zheng L, Lu Z, et al. Mesenchymal stem cells negatively regulate CD4 + T cell activation in patients with primary Sjögren′s syndrome through the miRNA-125b and miRNA-155 TCR pathway[J]. Mol Med Rep, 2021, 23(1):43. |
| [37] | Gong B, Zheng L, Huang W, et al. Murine embryonic mesenchymal stem cells attenuated xerostomia in Sjögren′s-like mice via improving salivary gland epithelial cell structure and secretory function[J]. Int J Clin Exp Pathol, 2020, 13(5):954-963. |
| [38] | Oni C, Mitchell S, James K, et al. Eligibility for clinical trials in primary Sjögren′s syndrome: lessons from the UK Primary Sjögren′s Syndrome Registry[J]. Rheumatology (Oxford), 2016, 55(3):544-552. |
| [39] | Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sjögren′s syndrome?[J]. PLoS One, 2015, 10(9):e0133907. |
| [40] | Arends S, Wolff LD, Nimwegen JV, et al. Composite of relevant endpoints for Sjögren′s syndrome(CRESS)[J]. Arthritis Rheumatol, 2020, 72(Suppl 10):1502. |
/
| 〈 |
|
〉 |
